These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 39218899)

  • 1. Suppression of the JAK/STAT pathway inhibits neuroinflammation in the line 61-PFF mouse model of Parkinson's disease.
    Hong H; Wang Y; Menard M; Buckley JA; Zhou L; Volpicelli-Daley L; Standaert DG; Qin H; Benveniste EN
    J Neuroinflammation; 2024 Sep; 21(1):216. PubMed ID: 39218899
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Suppression of the JAK/STAT Pathway Inhibits Neuroinflammation in the Line 61-PFF Mouse Model of Parkinson's Disease.
    Hong H; Wang Y; Menard M; Buckley J; Zhou L; Volpicelli-Daley L; Standaert D; Qin H; Benveniste E
    Res Sq; 2024 May; ():. PubMed ID: 38766241
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of the JAK/STAT Pathway Protects Against α-Synuclein-Induced Neuroinflammation and Dopaminergic Neurodegeneration.
    Qin H; Buckley JA; Li X; Liu Y; Fox TH; Meares GP; Yu H; Yan Z; Harms AS; Li Y; Standaert DG; Benveniste EN
    J Neurosci; 2016 May; 36(18):5144-59. PubMed ID: 27147665
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuroinflammatory gene expression profiles of reactive glia in the substantia nigra suggest a multidimensional immune response to alpha synuclein inclusions.
    Stoll AC; Kemp CJ; Patterson JR; Howe JW; Steece-Collier K; Luk KC; Sortwell CE; Benskey MJ
    Neurobiol Dis; 2024 Feb; 191():106411. PubMed ID: 38228253
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ciita Regulates Local and Systemic Immune Responses in a Combined rAAV-α-synuclein and Preformed Fibril-Induced Rat Model for Parkinson's Disease.
    Fredlund F; Jimenez-Ferrer I; Grabert K; Belfiori LF; Luk K; Swanberg M
    J Parkinsons Dis; 2024; 14(4):693-711. PubMed ID: 38728204
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting of the class II transactivator attenuates inflammation and neurodegeneration in an alpha-synuclein model of Parkinson's disease.
    Williams GP; Schonhoff AM; Jurkuvenaite A; Thome AD; Standaert DG; Harms AS
    J Neuroinflammation; 2018 Aug; 15(1):244. PubMed ID: 30165873
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dose-related biphasic effect of the Parkinson's disease neurotoxin MPTP, on the spread, accumulation, and toxicity of α-synuclein.
    Merghani MM; Ardah MT; Al Shamsi M; Kitada T; Haque ME
    Neurotoxicology; 2021 May; 84():41-52. PubMed ID: 33549656
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lewy body-like alpha-synuclein inclusions trigger reactive microgliosis prior to nigral degeneration.
    Duffy MF; Collier TJ; Patterson JR; Kemp CJ; Luk KC; Tansey MG; Paumier KL; Kanaan NM; Fischer DL; Polinski NK; Barth OL; Howe JW; Vaikath NN; Majbour NK; El-Agnaf OMA; Sortwell CE
    J Neuroinflammation; 2018 May; 15(1):129. PubMed ID: 29716614
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Age-dependent neurodegeneration and neuroinflammation in a genetic A30P/A53T double-mutated α-synuclein mouse model of Parkinson's disease.
    Rauschenberger L; Behnke J; Grotemeyer A; Knorr S; Volkmann J; Ip CW
    Neurobiol Dis; 2022 Sep; 171():105798. PubMed ID: 35750147
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intrastriatal injection of preformed alpha-synuclein fibrils alters central and peripheral immune cell profiles in non-transgenic mice.
    Earls RH; Menees KB; Chung J; Barber J; Gutekunst CA; Hazim MG; Lee JK
    J Neuroinflammation; 2019 Dec; 16(1):250. PubMed ID: 31796095
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Leveraging the preformed fibril model to distinguish between alpha-synuclein inclusion- and nigrostriatal degeneration-associated immunogenicity.
    Stoll AC; Sortwell CE
    Neurobiol Dis; 2022 Sep; 171():105804. PubMed ID: 35764290
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The involvement of JAK/STAT signaling pathway in the treatment of Parkinson's disease.
    Lashgari NA; Roudsari NM; Momtaz S; Sathyapalan T; Abdolghaffari AH; Sahebkar A
    J Neuroimmunol; 2021 Dec; 361():577758. PubMed ID: 34739911
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic efficacy of suppressing the Jak/STAT pathway in multiple models of experimental autoimmune encephalomyelitis.
    Liu Y; Holdbrooks AT; De Sarno P; Rowse AL; Yanagisawa LL; McFarland BC; Harrington LE; Raman C; Sabbaj S; Benveniste EN; Qin H
    J Immunol; 2014 Jan; 192(1):59-72. PubMed ID: 24323580
    [TBL] [Abstract][Full Text] [Related]  

  • 14. T cell infiltration and upregulation of MHCII in microglia leads to accelerated neuronal loss in an α-synuclein rat model of Parkinson's disease.
    Subbarayan MS; Hudson C; Moss LD; Nash KR; Bickford PC
    J Neuroinflammation; 2020 Aug; 17(1):242. PubMed ID: 32799878
    [TBL] [Abstract][Full Text] [Related]  

  • 15. LRRK2 modifies α-syn pathology and spread in mouse models and human neurons.
    Bieri G; Brahic M; Bousset L; Couthouis J; Kramer NJ; Ma R; Nakayama L; Monbureau M; Defensor E; Schüle B; Shamloo M; Melki R; Gitler AD
    Acta Neuropathol; 2019 Jun; 137(6):961-980. PubMed ID: 30927072
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The MHC class II transactivator modulates seeded alpha-synuclein pathology and dopaminergic neurodegeneration in an in vivo rat model of Parkinson's disease.
    Jimenez-Ferrer I; Bäckström F; Dueñas-Rey A; Jewett M; Boza-Serrano A; Luk KC; Deierborg T; Swanberg M
    Brain Behav Immun; 2021 Jan; 91():369-382. PubMed ID: 33223048
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intrastriatal injection of pre-formed mouse α-synuclein fibrils into rats triggers α-synuclein pathology and bilateral nigrostriatal degeneration.
    Paumier KL; Luk KC; Manfredsson FP; Kanaan NM; Lipton JW; Collier TJ; Steece-Collier K; Kemp CJ; Celano S; Schulz E; Sandoval IM; Fleming S; Dirr E; Polinski NK; Trojanowski JQ; Lee VM; Sortwell CE
    Neurobiol Dis; 2015 Oct; 82():185-199. PubMed ID: 26093169
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MLKL deficiency alleviates neuroinflammation and motor deficits in the α-synuclein transgenic mouse model of Parkinson's disease.
    Geng L; Gao W; Saiyin H; Li Y; Zeng Y; Zhang Z; Li X; Liu Z; Gao Q; An P; Jiang N; Yu X; Chen X; Li S; Chen L; Lu B; Li A; Chen G; Shen Y; Zhang H; Tian M; Zhang Z; Li J
    Mol Neurodegener; 2023 Dec; 18(1):94. PubMed ID: 38041169
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Microglia affect α-synuclein cell-to-cell transfer in a mouse model of Parkinson's disease.
    George S; Rey NL; Tyson T; Esquibel C; Meyerdirk L; Schulz E; Pierce S; Burmeister AR; Madaj Z; Steiner JA; Escobar Galvis ML; Brundin L; Brundin P
    Mol Neurodegener; 2019 Aug; 14(1):34. PubMed ID: 31419995
    [TBL] [Abstract][Full Text] [Related]  

  • 20. α-Synuclein Propagation Mouse Models of Parkinson's Disease.
    Uemura N; Ueda J; Okuda S; Sawamura M; Takahashi R
    Methods Mol Biol; 2021; 2322():119-130. PubMed ID: 34043198
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.